

Remarks

This Reply is in response to an Office Action mailed June 29, 2004. The Examiner issued a Restriction Requirement, identifying 4 groups of claims as follows:

- Group I: Claims 2-13, drawn to methods for making a medicament;
- Group II: Claims 14, 17, 19-26 drawn to methods for influencing glutamate receptor-controlled cells;
- Group III: Claims 14, 17-26 drawn to methods for influencing NMDA receptor-controlled cells; and
- Group IV: Claims 27-30 drawn to methods for treating a brain condition.

Applicant herein elects Group III claims, 14-16 and has redrafted claims 29-29 to depend from claim 14 or 27.


Applicant also elects (1-3)IGF-1 in claims 16-26.

Applicant reserves the right to prosecute withdrawn claims in divisional applications.

The Commissioner is authorized to charge any underpayment or credit any overpayment to Deposit Account No. 06-1325 for any matter in connection with this response, including any fee for extension of time, which may be required.

Respectfully submitted,

Date: December 15, 2004

By: 
D. Benjamin Borson
Reg. No. 42,349

FLIESLER MEYER LLP
Four Embarcadero Center, Fourth Floor
San Francisco, California 94111-4156
Telephone: (415) 362-3800